Association of C‐reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group

Muangchan, Chayawee; Harding, Sarah E; Khimdas, Sarit; Bonner, Alice D.; Baron, Murray; Pope, Janet

doi:10.1002/acr.21716

Cited by 102 publications

(100 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In support of this is the trend whereby the baseline median CRP was higher in ILD participants who deceased (9.2 mg/l vs 6.0 mg/l; p=0.066), and a higher proportion of participants in the deceased group had a CRP>8 mg/l (66.7% versus 33.3%; p=0.065). This is in keeping with findings where CRP>8mg/l was associated with mortality in SSc ILD patients (53,54) .…”

Section: Interstitial Lung Disease Survival In Systemic Sclerosissupporting

confidence: 91%

“…Muangchan and colleagues (2012) (53) demonstrated that a baseline C-reactive protein (CRP) > 8 mg/litre was associated with "disease activity, severity, poor pulmonary function, and shorter survival." This was supported by Liu et al (2013) (54) who found that baseline CRP predicted progression in FVC decline, and is associated with shorter survival.…”

Section: Interstitial Lung Disease Severity and Progression In Systemmentioning

confidence: 99%

See 1 more Smart Citation

Interstitial lung disease in South Africans with systemic sclerosis

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Interstitial Lung Disease Survival In Systemic Sclerosissupporting

confidence: 91%

Section: Interstitial Lung Disease Severity and Progression In Systemmentioning

confidence: 99%

Interstitial lung disease in South Africans with systemic sclerosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In order to better understand the relationship between disease duration and changes in expression of investigated molecules, patients were divided into those with short- and long-term disease. In agreement with previous studies, patients were considered as having short-term disease if disease duration was not longer than 3 years in dSSc or 5 years in lSSc measured from the first non-Raynaud symptom [29-31]. Accordingly, patients with dSSc in whom disease lasted longer than 3 years and patients with lSSc in whom disease lasted longer than 5 years were considered as having long-term disease.…”

Section: Methodsmentioning

confidence: 64%

High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis

et al. 2013

View full text Add to dashboard Cite

IntroductionSystemic sclerosis (SSc) is an autoimmune disease characterized by chronic inflammation, vascular injury and excessive fibrosis. CD163 is a scavenger receptor which affects inflammatory response and may contribute to connective tissue remodelling. It has recently been demonstrated that CD163 can bind and neutralize the TNF-like weak inducer of apoptosis (TWEAK), a multifunctional cytokine which regulates inflammation, angiogenesis and tissue remodelling. We aimed to investigate the relationships between serum levels of soluble CD163 (sCD163) and soluble TWEAK (sTWEAK) in relation to disease manifestations in SSc patients.MethodsThis study included 89 patients with SSc who had not received immunosuppressive drugs or steroids for at least 6 months and 48 age- and sex-matched healthy controls (HC) from four European centres. Serum concentrations of sTWEAK and sCD163 were measured using commercially available ELISA kits.ResultsThe mean serum concentrations of sTWEAK were comparable between SSc patients (mean +/- SD: 270 +/- 171 pg/mL) and HC (294 +/- 147pg/mL, P >0.05). Concentration of sCD163 and sCD163/sTWEAK ratio were significantly greater in SSc patients (984 +/- 420 ng/mL and 4837 +/- 3103, respectively) as compared to HC (823 +/- 331 ng/mL and 3115 +/- 1346 respectively, P <0.05 for both). High sCD163 levels and a high sCD163/sTWEAK ratio (defined as > mean +2SD of HC) were both associated with a lower risk of digital ulcers in SSc patients (OR, 95%CI: 0.09; 0.01, 0.71, and 0.17; 0.06, 0.51, respectively). Accordingly, patients without digital ulcers had a significantly higher sCD163 concentration and sCD163/sTWEAK ratio as compared to SSc patients with digital ulcers (P <0.01 for both) and HC (P <0.05 for both). A high sCD163/sTWEAK ratio, but not high sCD163 levels, was associated with greater skin involvement.ConclusionsThe results of our study indicate that CD163-TWEAK interactions might play a role in the pathogenesis of SSc and that CD163 may protect against the development of digital ulcers in SSc. Further studies are required to reveal whether targeting of the CD163-TWEAK pathway might be a potential strategy for treating vascular disease and/or skin fibrosis in SSc.

show abstract

“…Systemic inflammation is present in SSc at low grade [10] and increased serum levels of eosinophilic major basic protein have been described in early SSc [11]. We hypothesized therefore that eosinophils are activated in peripheral circulation facilitating their recruitment to the lung and that this is reflected in differentially expressed activation markers.…”

Section: Introductionmentioning

confidence: 96%

CD81 and CD48 show different expression on blood eosinophils in systemic sclerosis: new markers for disease and pulmonary inflammation?

Wuttge

Andreasson

Tufvesson

et al. 2015

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

Objective: In systemic sclerosis (SSc) related interstitial lung disease, elevated eosinophil counts in bronchoalveolar lavage are associated with worse outcome. We hypothesize that eosinophils are activated in the peripheral circulation, thereby increasing their recruitment to affected tissues and contributing to inflammation and fibrosis. The aim of this study was to characterize the blood eosinophils in SSc patients. Methods:Expressions of surface markers CD11b, CD44, CD48, CD54, CD69, CD81 and HLA-DR on CD16 low CD9 high expressing eosinophils were measured by flow cytometry in whole blood from SSc patients (n = 32) and controls (n = 11).Results: Expression of CD54, CD69 and HLA-DR were undetectable in all groups. CD44and CD11b expression levels were similar between groups. CD81 expression was lower in patients compared to controls independent of disease duration (p = 0.001). CD48 expression was increased in patients with a short disease duration (< 2 years) compared to both controls (p = 0.042) and patients with longer disease duration (p = 0.027). In patients with short disease duration, increased CD48 expression was associated with alveolar inflammation as measured by an increased concentration of alveolar nitric oxide (r = 0.76, p = 0.003). Conclusion:Blood eosinophils change phenotype during disease evolution in SSc, and CD48 expression may be used as a biomarker for pulmonary inflammation.

show abstract

Association of C‐reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group

Abstract: Objective. This study was performed to determine the prevalence of elevated C-reactive protein (CRP) levels and the significance of CRP in clinical parameters in systemic sclerosis (SSc; scleroderma) patients.

Cited by 102 publications

References 46 publications

Interstitial lung disease in South Africans with systemic sclerosis

Interstitial lung disease in South Africans with systemic sclerosis

High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis

CD81 and CD48 show different expression on blood eosinophils in systemic sclerosis: new markers for disease and pulmonary inflammation?

Contact Info

Product

Resources

About